Umbilical Cord Blood Banking Market

Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020

Umbilical Cord Blood Banking Market Segmented By Leukemia, Bone Marrow Failure Syndrome, Metabolic/Storage Diseases, Lymphoma, Immune Deficiencies Application with Private UCB Banks and Public UCB Banks Storage Option

  • October-2014
  • PMRREP3043
  • 127 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Table of Content

 

Chapter 1 Preface

1.1 Report Description 

1.2 Report Methodology

1.3 Assumptions

 

Chapter 2 Market Synopsis

 

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers 

3.3 Threat of New Entrants 

3.4 Threat of Substitutes

3.5 Intensity of Rivalry 

 

Chapter 4 Industry overview 

4.1 Market Definition 

4.2 Market Drivers 

      4.2.1 Increasing prevalence of chronic diseases enhances the market growth 

      4.2.2 Emerging field of regenerative medicines boost the market growth

      4.2.3 Initiatives by various government associations have increased the importance of UCB 

4.3 Impact Analysis of Market Drivers 

4.4 Market Restraints

      4.4.1 Strict license and accreditation procedures impede the market growth

      4.4.2 High cord blood banking fee in private UCB banks 

4.5 Impact Analysis of Market Restraints 

4.6 Market Tends

      4.6.1 UCB is gaining popularity in allogeneic hematopoietic stem cell transplantation 

      4.6.2 Umbilical cord tissue storage is gaining importance in UCB banking market 

 

Chapter 5 Global Market Size and Forecast 

 

Chapter 6 Market Size and Forecast by Therapeutic Application of UCB 

6.1 Leukemia 

6.2 Bone Marrow Failure Syndrome 

6.3 Metabolic/Storage Diseases

6.4 Lymphoma 

6.5 Immune Deficiencies 

 

Chapter 7 Market Size and Forecast by Storage Option 

7.1 Private UCB Banks 

7.2 Public UCB Banks 

 

Chapter 8 Market Size and Forecast by Geography 

8.1 North America 

      8.1.1 Scenario in the U.S. 

              8.1.1.1 Legislations

      8.1.2 Scenario in Canada 

8.2 Europe 

      8.2.1 Scenario in the U.K. 

              8.2.1.1 Legislations 

      8.2.2 Scenario in France 

      8.2.3 Scenario in the Germany 

      8.2.4 Scenario in Spain 

      8.2.5 Scenario in Italy

      8.2.6 Scenario in Belgium 

8.3 Asia Pacific 

      8.3.1 Scenario in China 

      8.3.2 Scenario in India 

      8.3.3 Scenario in Japan 

      8.3.4 Scenario in Australia

      8.3.5 Scenario in Singapore 

 

Chapter 9 Competitive Scenario 

9.1 Competitive Benchmarking 

 

Chapter 10 Company Profiles 

10.1 Cord Blood Registry Systems, Inc.

      10.1.1 Company overview

      10.1.2 Products and services 

      10.1.3 Financial performance 

      10.1.4 Recent developments 

10.2 Cordlife Group Limited

      10.2.1 Company overview 

      10.2.2 Products and services 

      10.2.3 Financial performance 

      10.2.4 Recent developments

10.3 Cord Blood America, Inc.

      10.3.1 Company overview 

      10.3.2 Products and services 

      10.3.3 Financial performance 

      10.3.4 Recent developments 

10.4 NeoStem, Inc.

      10.4.1 Company overview 

      10.4.2 Products and services 

      10.4.3 Financial performance 

      10.4.4 Recent developments

10.5 Cryo-Cell International, Inc. 

      10.5.1 Company overview

      10.5.2 Products and services 

      10.5.3 Financial performance 

      10.5.4 Recent developments 

10.6 ViaCord

      10.6.1 Company overview 

      10.6.2 Products and services 

      10.6.3 Financial performance 

      10.6.4 Recent developments 

10.7 Esperite N.V.

      10.7.1 Company overview 

      10.7.2 Products and services 

      10.7.3 Financial performance 

      10.7.4 Recent developments

10.8 StemCyte

      10.8.1 Company overview 

      10.8.2 Products and services 

      10.8.3 Financial performance 

      10.8.4 Recent Developments 

10.9 Smart Cells International, Ltd.

      10.9.1 Company overview 

      10.9.2 Products and services

      10.9.3 Financial performance

      10.9.4 Recent developments

10.10 China Cord Blood Corporation

      10.10.1 Company overview

      10.10.2 Products and Services 

      10.10.3 Financial performance 

      10.10.4 Recent developments

Find Out More about the Report Coverage

List of Tables

List of Tables

TABLE 1: Market Snapshot: Global market for UCB banking (2014 and 2020)

TABLE 2: Application of UCB in disease treatment

TABLE 3: Drivers for UCB banking market: Impact analysis

TABLE 4: Restraints for UCB banking market: Impact analysis

TABLE 5: Global market for UCB banking, by geography, 2010 – 2013 (USD million)

TABLE 6: Global market for UCB banking, by geography, 2014 – 2020 (USD million)

TABLE 7: Global market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 8: Global market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 9: Global market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 10: Global market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 11: Global market for therapeutic application of UCB in leukemia, by geography, 2010 – 2013 (USD million)

TABLE 12: Global market for therapeutic application of UCB in leukemia, by geography, 2014 – 2020 (USD million)

TABLE 13: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2010 – 2013 (USD million)

TABLE 14: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2014 – 2020 (USD million)

TABLE 15: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2010 – 2013 (USD million)

TABLE 16: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2014 – 2020 (USD million)

TABLE 17: Global market for therapeutic application of UCB in lymphoma, by geography, 2010 – 2013 (USD million)

TABLE 18: Global market for therapeutic application of UCB in lymphoma, by geography, 2014 – 2020 (USD million)

TABLE 19: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2010 – 2013 (USD million)

TABLE 20: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2014 – 2020 (USD million)

TABLE 21: Global market for private UCB banks, by geography, 2010 – 2013 (USD million)

TABLE 22: Global market for private UCB banks, by geography, 2014 – 2020 (USD million)

TABLE 23: Global market for public UCB banks, by geography, 2010 – 2013 (USD million)

TABLE 24: Global market for public UCB banks, by geography, 2014 – 2020 (USD million)

TABLE 25: The North American market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 26: The North American market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 27: The North American market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 28: The North American market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 29: The North American market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 30: The North American market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 31: The U.S. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 32: The U.S. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 33: Canada market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 34: Canada market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 35: The European market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 36: The European market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 37: The European market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 38: The European market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 39: The European market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 40: The European market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 41: The U.K. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 42: The U.K. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 43: French market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 44: French market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 45: German market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 46: German market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 47: Spanish market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 48: Spanish market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 49: Italian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 50: Italian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 51: Belgium market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 52: Belgium market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 53: Asia Pacific market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 54: Asia Pacific market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 55: Asia Pacific market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 56: Asia Pacific market for UCB banking, by therapeutic application, 2014 – 2020 (USD million)

TABLE 57: Asia Pacific market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 58: Asia Pacific market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 59: Chinese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 60: Chinese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 61: Indian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 62: Indian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 63: Japanese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 64: Japanese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 65: Australian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 66: Australian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 67: Singapore market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 68: Singapore market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 69: CBR major products and services categories

TABLE 70: Cordlife’s service categories

TABLE 71: CBAI’s product and services categories

TABLE 72: NeoStem’s major service categories

TABLE 73: Cryo-Cell’s service category

TABLE 74: ViaCord’s service categories

TABLE 75: Esperite’s major product and services categories

TABLE 76: StemCyte’s product and services categories

TABLE 77: Smart Cells’s service categories

TABLE 78: CCBC’s service category

Explore Persistence Market Research’s expertise in promulgation of the business !

List of Chart

List of Figures

FIG. 1: UCB banking market: Porter\'s five forces analysis

FIG. 2: Steps involved in UCB collection and banking

FIG. 3: Major therapeutic applications of UCB

FIG. 4: Global UCB banking market share, by region, by value, 2013

FIG. 5: Global UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 6: Global UCB banking market share, by storage option, by value, 2013

FIG. 7: Global therapeutic application of UCB for leukemia market share, by region, by value, 2013

FIG. 8: Global therapeutic application of UCB for bone marrow failure syndrome market share, by region, by value, 2013

FIG. 9: Global therapeutic application of UCB in metabolic/storage diseases market share, by region, by value, 2013

FIG. 10: Global therapeutic application of UCB for lymphoma market share, by region, by value, 2013

FIG. 11: Global therapeutic application of UCB for immune deficiencies market share, by region, by value, 2013

FIG. 12: Global private UCB banks market share, by region, by value, 2013

FIG. 13: Global public UCB banks market share, by region, by value, 2013

FIG. 14: The North American UCB banking market share, by country, by value, 2013

FIG. 15: The North American UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 16: The North American UCB banking market share, by storage option, by value, 2013

FIG. 17: The U.S. UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 18: Canada UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 19: The European UCB banking market share, by country, by value, 2013

FIG. 20: The European UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 21: The European UCB banking market share, by storage option, by value, 2013

FIG. 22: The U.K. UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 23: French UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 24: German UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 25: Spanish UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 26: Italian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 27: Belgium UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 28: Asia Pacific UCB banking market share, by country, by value, 2013

FIG. 29: Asia Pacific UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 30: Asia Pacific UCB banking market share, by storage option, by value, 2013

FIG. 31: Chinese UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 32: Indian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 33: Japanese UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 34: Australian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 35: Singapore UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 36: Competitive landscape of UCB banking market

FIG. 37: Cordlife revenue and profit, 2012 – 2014 (USD million)

FIG. 38: CBAI revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 39: NeoStem revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 40: Cryo-Cell revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 41: Esperite’s revenue and profit, 2011 – 2013 (USD million)

FIG. 42: CCBC’s revenue and net income, 2012 – 2014 (USD million)

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Description

Umbilical cord blood (UCB) is collected from the umbilical cord of a newborn baby and also retrieved from the placenta after delivery. It is enriched with adult stem cells and these stem cells play a vital role in regulating all biological activities and in developing tissues in the human body. Many types of stem cells are present in UCB including hematopoietic stem cells and mesenchymal stem cells. Hematopoietic stem cells give rise to all the other blood cells. Hematopoietic stem cells are severely damaged in people suffering from bone marrow diseases, malignancies, inherited metabolic disorders, and immunological disorders. Mesenchymal stem cells are involved in the development of tissues such as cartilage, bone, fat, new blood vessels, and cardiac muscles.

UCB is used in clinical procedures associated with regenerative medicines. For instance, UCB-derived stem cells are used in hematopoietic stem cell transplantation (HSCT) for the treatment of life-threatening diseases such as leukemia and type I diabetes in children and adults. In addition, UCB is also used in the treatment of diseases such as bone marrow disorders, circulatory diseases, heart problems, neurological diseases, and cartilage disorders.

Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market.

However, strict license and accreditation procedures impede the growth of UCB banking market. In addition, high banking cost in private UCB banks is also hampering the growth of UCB banking market. Allogeneic hematopoietic stem cell transplantation and cord tissue storage are some of the major trends in UCB banking market.

North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region.

In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe.

However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world.

The report provides in-depth analysis and estimation of the UCB market from 2014 to 2020, considering 2014 as the base year for calculation. Additionally, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.

Recommendations

Methyl Ethyl Ketone Market

The expected value of the global MEK market is expected to be US$ 800.2 Mn in 2018 and the market is estimated to reach US$ 1,055.6 Mn by the end of forecast period..

Propylene Glycol Ether Market

The global propylene glycol ether market is estimated to have been valued at US$ 1,604.1 Mn by 2017 end and is expected to reach US$ 2,088.4 Mn by the end of 2026 while expanding at a CAGR of 3.0% over the forecast period. .

Polyester Polyols Market

Polyester Polyols Market was valued at US$ 7,788.7 Mn in 2017 and is projected to rise to a valuation of US$ 11,963.6 Mn by the end of 2025..

White Spirit Market

White Spirits Market are of four types - Type 1, Type 2, Type 3, and Type 0, which are categorized on their aromatic content basis. White spirits are consumed in a wide range of applications such as paint thinners, cleaning solvents, degreasing solvents, fuels, and disinfectants, among others..

Our Clients

Our Clients